Vizimpro(dacomitinib)
Vizimpro (dacomitinib) is a small molecule pharmaceutical. Dacomitinib was first approved as Vizimpro on 2018-09-27. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. It is known to target epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-2, and receptor tyrosine-protein kinase erbB-4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| respiratory tract diseases | D012140 |
Trade Name
FDA
EMA
Vizimpro
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vizimpro | New Drug Application | 2023-10-13 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| non-small-cell lung carcinoma | — | D002289 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
DACOMITINIB, VIZIMPRO, PFIZER | |||
| 2025-09-27 | ODE-206, ODE-213 | ||
| 2023-09-27 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
64 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 7 | 13 | 4 | 1 | 6 | 30 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 7 | 8 | 4 | 1 | 5 | 24 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 3 | 3 | — | — | 1 | 7 |
| Neoplasms | D009369 | — | C80 | 5 | 2 | — | — | — | 7 |
| Squamous cell carcinoma | D002294 | — | — | 2 | 4 | — | — | 1 | 7 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | 3 | — | — | — | 5 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 4 | — | — | — | 4 |
| Squamous cell neoplasms | D018307 | — | — | 1 | 3 | — | — | — | 4 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | 2 | — | — | 1 | 4 |
| Adenocarcinoma | D000230 | — | — | 2 | 1 | — | — | — | 3 |
| Recurrence | D012008 | — | — | 1 | 1 | — | — | — | 2 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | 2 | — | — | — | 2 |
Show 8 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 7 | — | — | — | — | 7 |
| Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Hematologic neoplasms | D019337 | — | — | 1 | — | — | — | — | 1 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | — | — | — | — | 1 |
Show 26 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dacomitinib |
| INN | dacomitinib |
| Description | Dacomitinib is a member of the class of quinazolines that is 7-methoxyquinazoline-4,6-diamine in which the amino group at position 4 is substituted by a 3-chloro-4-fluorophenyl group and the amino group at position 6 is substituted by an (E)-4-(piperidin-1-yl)but-2-enoyl group. It has a role as an epidermal growth factor receptor antagonist and an antineoplastic agent. It is a member of quinazolines, a member of piperidines, an enamide, a member of monochlorobenzenes, a member of monofluorobenzenes, a tertiary amino compound, a secondary amino compound and a secondary carboxamide. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1 |
Identifiers
| PDB | — |
| CAS-ID | 1110813-31-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2110732 |
| ChEBI ID | — |
| PubChem CID | 11511120 |
| DrugBank | DB11963 |
| UNII ID | 2XJX250C20 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ERBB4
ERBB4
Organism
Homo sapiens
Gene name
ERBB4
Gene synonyms
HER4
NCBI Gene ID
Protein name
receptor tyrosine-protein kinase erbB-4
Protein synonyms
avian erythroblastic leukemia viral (v-erb-b2) oncogene homolog 4, human epidermal growth factor receptor 4, p180erbB4, Proto-oncogene-like protein c-ErbB-4, Tyrosine kinase-type cell surface receptor HER4, v-erb-a erythroblastic leukemia viral oncogene homolog 4, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4
Uniprot ID
Mouse ortholog
Erbb4 (13869)
receptor tyrosine-protein kinase erbB-4 (Q61527)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,222 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
662 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use